Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04832971 · ClinicalTrials.gov registry record · Phase 2
Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
A Phase 2 study of Mixed Dyslipidemia, sponsored by Arrowhead Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
- 20
- Study locations
NCT04832971: Completed Phase 2 study of Mixed Dyslipidemia, sponsored by Arrowhead Pharmaceuticals.
NCT04832971 is a Phase 2 study of Mixed Dyslipidemia that has completed, run by Arrowhead Pharmaceuticals. The registered enrollment target is 204 participants, below the 671-participant average among 3 other Mixed Dyslipidemia trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04832971, a Phase 2 study of Mixed Dyslipidemia, has completed, sponsored by Arrowhead Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will initially receive 2 subcutaneous injections of ARO-ANG3 or placebo. Participants who complete the double-blind treatment period may opt to continue in an open-label extension during which they will receive up to 8 doses of ARO-ANG3.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ARO-ANG3
Study Locations (20)
Florida
- Research Site 7 - Hialeah
- Research Site 17 - Miami
- Research Site 8 - Port Orange
Other
- Research Site 18 - Nedlands
- Research Site 12 - Québec
- Research Site 9 - Québec
North Carolina
- Research Site 15 - Greensboro
- Research Site 2 - Morehead City
California
- Research Site 5 - Huntington Park
Minnesota
- Research Site 24 - Minneapolis
Nebraska
- Research Site 10 - Omaha
Nevada
- Research Site 23 - Las Vegas
New York
- Research Site 22 - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2021-06-28 |
| Est. Completion | 2024-09-25 |
| Phase | Phase 2 |
What the finished NCT04832971 record still lists
NCT04832971 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, below the 671-participant average among 3 other Mixed Dyslipidemia trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Mixed Dyslipidemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04832971 names 20 study sites across 15 states, led by Florida, Other, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04832971 about?
NCT04832971 is a clinical study titled "Study of ARO-ANG3 in Adults With Mixed Dyslipidemia". The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will initially receive 2 subcutaneous injections of ARO-ANG3 or placebo. Participants who complete the double-blind treatment period may opt to continue in an open-lab...
What is the current status of trial NCT04832971?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2021-06-28. Estimated completion is 2024-09-25.
What conditions does trial NCT04832971 study?
This clinical trial studies the following conditions: Mixed Dyslipidemia.
What interventions are being tested in trial NCT04832971?
The interventions under investigation include: Placebo (DRUG), ARO-ANG3 (DRUG).
Who is sponsoring clinical trial NCT04832971?
This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04832971 being conducted?
This trial has 20 study locations across California, Florida, Minnesota, Nebraska, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mixed Dyslipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Patients With Mixed Dyslipidemia
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
COMPLETED · Phase 3
-
Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI